A recent study underscores the crucial role and clinical potential of the DSB repair pathway in augmenting the efficacy of PARP inhibitors for treating drug-resistant ovarian and triple-negative breast cancer, achieved through the synergistic action of SIK2 inhibitors, which both impairs the DSB repair pathway and amplifies PARP inhibitor sensitivity [38]. The gene discussed is PARP1; the disease is triple-negative breast carcinoma.